Literature DB >> 7690169

Study of activities of arginase, hexosaminidase, and leucine aminopeptidase in prostate fluid.

A Z Vafa1, P K Grover, T G Pretlow, M I Resnick.   

Abstract

Our previous studies demonstrated that extracts of the cancerous prostate tissues exhibit increased activities of arginase and hexosaminidase and decreased activity of leucine aminopeptidase. In an endeavor to devise a reliable, noninvasive and cost effective method for the diagnosis of prostate carcinoma, prostate fluids collected from 123 patients were analyzed for arginase, hexosaminidase, and leucine aminopeptidase. Based on the clinical diagnoses, the patients were divided into four groups: 13 men with chronic prostatitis, 29 with no recognized prostatic lesions, 63 with benign prostatic hyperplasia, and 18 with prostate cancer. The prostate fluids had no detectable arginase activity. The means of the total (units/mL) and the specific activities (units/mg of protein) of hexosaminidase and leucine aminopeptidase varied, albeit there were no significant differences in the four groups of patients recruited in this study. It was concluded that the profiles of enzymes in prostate fluids might differ from that in the secreting prostate tissues and that the results of enzyme analysis in prostate fluids for the diagnosis of cancer should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690169     DOI: 10.1016/0090-4295(93)90636-o

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

1.  Evaluation of serum arginase activity in benign prostatic hypertrophy and prostatic cancer.

Authors:  S Elgün; A Keskineğe; E Yilmaz; S Baltaci; Y Bedük
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

2.  Total protein and acid phosphatase concentrations in prostatic fluid from patients with BPH compared to carcinoma.

Authors:  E D Kim; N D Smith; J T Grayhack
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.